Dr. Raja T

DNB Medical Oncology Teacher. (Sub Speciality Teaching Program) in Apollo Speciality Hospital, Tamil Nadu, Chennai,India- From 2014 to till date

Senior Consultant in Medical

Oncology& Senior Consultant in BMT in Apollo Speciality Hospital, Tamil Nadu, Chennai,India- From 1999 to till date

Member of the Inspection Commission in University of Madras, Tamil Nadu, Chennai, India- 2011

DNB Medical Oncology Teacher in V.S. Hospital, Tamil Nadu, Chennai, India- 2009

Adjunt Associate ProfessorUniversity of Queensland, School of Medicine, Brisbane- 2009

Junior Consultant in Medical

Oncology and BMT Apollo Speciality Hospital, Tamil Nadu, Chennai, India- From 1997 Sep to 1999 Jan

Senior Registrar in Apollo Speciality Hospital, Tamil Nadu, Chennai, India- From 1996 to 1997 Sep

Honorary Observer in BMT The Royal Free Hospitals, London- From 1998 to 1998 Jul

April 2015 to till date Breast Cancer Registry to Collate Data on Epidemiology andTreatment Patterns & Outcomes of Breast Cancer in India

2012 A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs.MabThera® plus cyclophosphamide, vincristine,prednisone, followed by GP2013 or MabThera® maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma.

From 2012 to till dateA randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patients with HER2-positive and hormone receptor-positive advanced (metastatic or locally advanced) breast cancer

From 2012 to till dateA Randomised, Multi-centre, Double-blind, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Two Anti-CD20 Monoclonal Antibodies in Combination with CHOP in Patients with CD20-Positive Diffuse Large B-cell Lymphoma

From 2012 to till dateA Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial To Evaluate The Efficacy Of T-Dm1 Compared With Treatment Of Physician’s Choice In Patients With Her2-Positive Metastatic Breast Cancer Who Have Received At Least Two Prior Regimens Of Her2-Directed Therapy

From 2012to till dateA Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus CVP vs. MabThera® plus CVP, Followed by GP2013 or MabThera® Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma

From 2012to till datePrincipal Investigator for An Extending molecular responses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd)

From 2009 to till date Principal Investigator in a phase II biomarker identification trial for Erlotinib (Tarceva®) in patients with advanced pancreatic carcinoma (MARK)

From 2009 to till date Principal Investigator for A Randomized, Double – blind, Multicenter, Phase III study of Brivanib versus Sorafenib as first – line treatment in patients with advanced Hepatocellular Carcinoma (HCC) The BRISK FL Study

From 2007 to till date -Principal Investigator a Phase III, randomized, double blind, multicenter, placebo-controlled study of adjuvant Lapatinib in women with early Stage Erb2 over expressing breast cancer.
Experience In Clinical Trials:

From 2011 to 2011Principal Investigator for A Open Label, Non –Controlled, on Randomized, Interventional Pilot study to evaluate the response rate after Induction therapy with Docetaxel (T) and Cisplatin (P) in Unrespectable locally Advanced Squamous Cell Carcinoma of Head and Neck.

From 2011 toDec 2011 Principal Investigator for A randomized, open label, active controlled, comparative parallel group and multicentric study :Efficacy and safety of Paclitaxel Nano Dispersion Concentrate for injection (PICN) in subjects with metastatic breast cancer

From 2011 to 2011 Principal Investigator for A Multicentric open label Phase III study to evaluate the safety and efficacy of Rituximab (Zenotech) in Non Hodgkin’s Lymphoma.

From 2009 to Feb 2012 Principal Investigator for a A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have failed or are Intolerant to Sorafenib (BRISK-PS)

From 2008 to Nov 2011 - Principal Investigator in a phase 2, multicenter, open label, randomized trial of AMG 706 or Bevacizumab in combination

2009 - Principal Investigator in a randomized, multi-centre, open label study to evaluate safety and efficacy of PEG G-CSF as compared to Grafeel® in the Prophylaixis of severe Neutropenia in cancer patients receiving cytotoxic chemotherapy

2008 - Principal Investigator in a randomized, double-blind Phase III study of Gemcitabine + against 013736 versus Gemcitabine + placebo in first line treatment with patients with locally advanced, resectable or metastatic pancreatic cancer

2007 to 2008 - Principal Investigator in a Phase III, randomized, open labelled, multicentre study of XRP6258 at 25mg/m² in combination with prednisone for the treatment of hormone refractory metastatic prostate cancer previously treated with Taxotore® containing regimen with Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer.

2006 to 2008 - Principal Investigator in prospective, non-comparative, open-label, multicentre study to evaluate safety and efficacy of Pegfilgrastim (IPL-PO5) for prevention of Neutropenia in the patients receiving chemotherapy.

2006 Apr to 2010-Principal Investigator in Phase III trial on Pixantrone for third line single treatment of patients with relapsed aggressive Non – Hodgkins Lymphoma

2006 Apr to 2010- Principal Investigator in Phase III trial on Glufosfamide compared with best supportive care in metastatic pancreatic Adenocarcinoma previously treated with Gemcitabine.

Principal Investigator in Phase III trial on Glufosfamide compared with best supportive care in metastatic pancreatic Adenocarcinoma previously treated with Gemcitabine

2005 Mar to 2006 - Principal Investigator in Phase III, randomized, double - blind, comparative study of Micafungin (FK 463) Versus Caspofungin as antifungal treatment in patient with Invasive Candidiasis or Candidemia.

2003 Oct to 2004 – Principal Investigator in Phase III trial on Multicentre double blind comparative randomised study to evaluate the efficacy and safety of Micafunginvs liposomal Amphotericin B (Ambisome) in the treatment of invasive Candidiasis And Candidemia.

2003 Aug to Dec 2004-Principal Investigator in open labelled observational PMS study using Octreotide long acting in patients of inoperable Hepatocellular Carcinoma.

2003 Jan to Dec 2004- Principal Investigator in observational PMS study on ZOMETA in patients with prostate cancer, breast cancer & Multiple Myeloma.

2003 Oct to Dec 2004- Principal Investigator in Phase II trial on ALIMTA in patients with advanced non small cell lung cancer who have had prior chemotherapy.

1999 Sep to Dec 2000-Co-Investigator in multicentric, multinational phase II - trial on head and Neck Squamous Cell Carcinoma with Gemcitabine plus Cisplatin chemotherapy.